Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer’s disease
Elena Solopova, Wilber Romero-Fernandez, Hannah Harmsen, Lissa Ventura-Antunes, Emmeline Wang, Alena Shostak, Jose Maldonado, Manus J Donahue, Daniel Schultz, Thomas M Coyne, Andreas Charidimou, Matthew Schrag · 2023
Read Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer’s disease by Elena Solopova, Wilber Romero-Fernandez, Hannah Harmsen, Lissa Ventura-Antunes, Emmeline Wang, Alena Shostak, Jose Maldonado, Manus J Donahue, Daniel Schultz, Thomas M Coyne, Andreas Charidimou, Matthew Schrag (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10716177.txt.
Description
Elena Solopova and ten co-authors report a fatal case in 2023 tied to a new Alzheimer's drug. A seventy-nine-year-old woman joined the big trial of lecanemab, a drug that clears amyloid from the brain. She first drew placebo, then entered the open phase where all patients got the drug.
After her third dose she had a seizure with speech arrest. Scans showed swelling in many brain spots and a surge in tiny bleeds. Steroids and seizure drugs did not stop the decline, and she died in five days. Autopsy found severe amyloid in vessel walls with inflammation, plus two copies of a risk gene.
Catalog record
| CREATOR | Elena Solopova, Wilber Romero-Fernandez, Hannah Harmsen, Lissa Ventura-Antunes, Emmeline Wang, Alena Shostak, Jose Maldonado, Manus J Donahue, Daniel Schultz, Thomas M Coyne, Andreas Charidimou, Matthew Schrag |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |